Eye on Pharma: High Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP Aflibercept Opinion
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some preferred drug lists in favor of biosimilars and Evernorth will offer an interchangeable ustekinumab biosimilar at no cost to patients; …